Psylink is a biotechnology company established in 2020 by Evaldas Ciplys and Laura Martinkute Korsakova. Headquartered in Vilnius, Lithuania, the company focuses on developing cutting-edge psychedelic drug therapies aimed at addressing mental health disorders. Psylink has raised significant funding, including over €500k in a pre-seed round as of 2025. The company's strategic initiatives focus on harnessing the therapeutic potential of psychedelic compounds to create novel treatment options where traditional interventions fall short.
| Attribute | Information |
|---|---|
| Founding Date | 2020 |
| Headquarters | Vilnius, Lithuania |
| Founders | Evaldas Ciplys, Laura Martinkute Korsakova |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Coinvest Capital, Firstpick, BSV Ventures |
| Industry | Biotechnology |
| Number of Employees | 2-10 |
Founded in 2020, Psylink began as a pioneering biotech startup in Lithuania, setting its sights on innovating psychedelic drug treatments. The brainchild of Evaldas Ciplys and Laura Martinkute Korsakova, Psylink entered a niche yet burgeoning domain where existing mental health treatments had shown limitations. The initial phase focused on building a sustainable platform for the bioproduction of psychedelics using engineered yeast cells—a method devised to ensure ecological sustainability while producing effective drugs. Rapidly gaining attention from investors, Psylink secured its first rounds of funding to bolster research efforts, propelling the company into a significant role within the mental health biotech sector.
Psylink's business model is founded on the creation of science-driven therapies targeting mental health disorders with psychedelic agents. The company has carved a niche in biosynthetically producing compounds like psilocybin, adhering strictly to GMP protocols for pharmaceutical applications. Major achievements include:
Currently, Psylink operates at the forefront of biotechnology, merging neuroscience with natural product research. With its sustainable production methods, the company is well-positioned in the industry as a provider of alternative mental health therapies, pivotal for cases that fail traditional treatments. Psylink's commitment to ecological integrity in compound production positions them advantageously in a climate-conscious market, bolstering their competitive edge.
Psylink stands as a significant player in the biotechnology field with its purpose-driven approach to mental health treatment using psychedelic compounds. Highlighted by their innovation in sustainable production methods and breakthrough R&D, the company not only addresses a crucial gap in mental healthcare but also commits to environmental sustainability. As Psylink continues to evolve, its trajectory points towards becoming a leader in alternative therapies for mental health, potentially revolutionizing the industry with effective, natural-based solutions.